Canaccord Genuity Group Has Lowered Expectations for COMPASS Pathways (NASDAQ:CMPS) Stock Price

COMPASS Pathways (NASDAQ:CMPS - Free Report) had its price target lowered by Canaccord Genuity Group from $23.00 to $15.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also commented on CMPS. HC Wainwright dropped their price target on shares of COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research report on Thursday, February 27th. They issued a "buy" rating and a $11.00 target price on the stock. Maxim Group cut their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $21.83.

COMPASS Pathways Stock Up 4.9 %

Shares of CMPS stock traded up $0.18 on Friday, reaching $3.85. 991,211 shares of the stock were exchanged, compared to its average volume of 725,805. The company has a market capitalization of $263.42 million, a price-to-earnings ratio of -1.75 and a beta of 2.28. The business's 50 day moving average price is $4.06 and its 200 day moving average price is $5.21. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways has a twelve month low of $3.17 and a twelve month high of $12.57.

Remove Ads

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, sell-side analysts expect that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of COMPASS Pathways

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in COMPASS Pathways in the fourth quarter valued at $41,000. Flagship Harbor Advisors LLC acquired a new position in COMPASS Pathways in the 4th quarter valued at about $43,000. Wealthfront Advisers LLC acquired a new position in COMPASS Pathways in the 4th quarter valued at about $43,000. Conservest Capital Advisors Inc. raised its stake in COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock valued at $51,000 after acquiring an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in COMPASS Pathways during the 4th quarter worth approximately $54,000. Institutional investors and hedge funds own 46.19% of the company's stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.